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T
he front sheet of the first grant I ever 
applied for (from the American Heart 
Association) had two questions; the fi rst 
was whether the applicant was asking 
a new or an old question, and the second was 
whether one was approaching it with a new or 
an old method. Th is was intimidating to a nov-
ice, since it was obvious from the phrasing that 
the highest priority would be given to those 
approaching new questions with new methods. 
Here, in bare words the dictatorship of the new 
was made fully evident. Although I got the grant 
— even though I remember asking old questions 
using slightly modifi ed old methods — I became 
obsessed from then on with the relation between 
the right question and the appropriate method 
for answering it. Everybody says that asking the 
important question is what diff erentiates great 
research from mediocre; and once you ask it, 
we are told, designing the experimental method 
to answer it is a ‘piece of cake.’ We have all been 
brought up to hold these truths to be self-evident, 
but like all truisms, these ideas are generalizations 
that are often too trivial and obvious and are 
sometimes incorrect in detail. In many instances, 
identifying the right question is a retrospective 
aff air; it comes aft er you do the experiment, not 
before. In others, the question has been sitting 
around in the fi eld in plain sight of everybody, 
but the method for its answer requires insight and 
creativity. Further, what (or who) determines the 
right method to answer any question? Is it the 
experience of others, the random insights of an 
inventor from a diff erent fi eld, the creativity of 
an individual scientist, or a team eff ort that, by 
peer review, forces an investigator to answer ques-
tions the way the scientifi c community wants? Of 
course all of the above are correct, though obvi-
ously not simultaneously.
Let me start by discussing a lecture given by 
Alan Hodgkin, the Nobel laureate physiologist 
who discovered (with Huxley) the ionic basis of 
nerve conduction. Th e papers by Hodgkin and 
Huxley were celebrated not only for their content 
but also for their style, in which clearly articulated 
questions were followed by a systematic analysis 
of the results that went in a strict ironclad logical 
manner from one sub-question to another, reach-
ing what appeared to be an inevitable conclusion 
at the end. In his delightful lecture given at the 
centenary meeting of the (British) Physiological 
Society in Cambridge in 1976, Hodgkin confessed 
that he always wrote his scientifi c papers with a 
format where the question came fi rst, a prelimi-
nary observation suggested a tentative answer, 
and further experiments confi rmed these initial 
answers.1 He then went on to say that oft en experi-
ments done for some perfectly “dotty” reason give 
logical answers to questions that had never been 
asked. Implicit here is that the important ques-
tions were discovered aft er an experiment was 
designed for a diff erent purpose. Of course, what 
is required then is that the investigator recog-
nize that these questions are actually signifi cant 
and need to be pursued. Hodgkin concluded by 
invoking chance and good fortune, which play 
an important part in these endeavors. But then, 
chance, as is said (presumably by Pasteur), favors 
the prepared mind.
Perhaps Hodgkin is right that fi nding the right 
question is oft en a retrospective aff air, but once 
one has a question the experimental design and 
methods would seem to be more straightforward. 
For each question there is bound to be the one 
appropriate method. But here again, you might 
fi nd out that there are diff erent ways to answer the 
same question. It is not uncommon in competitive 
fi elds to see two or three papers published in the 
same issue of a journal that all address the same 
question but use diff erent methods. Are there 
ways to vet these methods beforehand? In basic 
science there are traditional ways of answering 
questions, and imaginative investigators will gain 
kudos if they design a new and original method 
to answer an important question. But it is easy to 
refer to the literature for specifi c methods of ana-
lysis. It is no accident that the most cited paper in 
the history of modern biologic research addresses 
the measurement of proteins in a sample.2 But 
in patient-oriented research, important studies 
oft en require vast resources; they oft en need large 
numbers of patients to provide suffi  cient statisti-
cal power to determine a decisive answer within 
a reasonable amount of time, and hence they are 
oft en multicenter trials. Th e need for this large 
cohort of patients requires strict controls over the 
collection of data by disparate groups of clinician 
investigators. Th e collection of samples must be 
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standardized, and the laboratory methods must 
be suffi  ciently regimented so that it is oft en best 
to have a centralized facility for analysis. Th e sta-
tistical controls are critical and are oft en provided 
by professional statisticians. These and many 
other requirements end up costing large sums 
of money. Should we, then, allow peer review to 
judge the signifi cance of these studies only aft er 
the studies have been conducted? Suppose there 
was an obvious error that could easily have been 
corrected; the whole fi eld loses if the results are 
thus ‘underpowered’ or simply poorly enough 
designed that they are not decisive. All of this is 
to show that there is a need for peer review before 
enormous sums of money are expended. Hence, 
we feel it is our duty as citizens and as scientists 
to provide peer review for studies’ experimental 
design, with or without preliminary feasibility 
results, before any results are obtained. Th is issue 
of Kidney International contains the fi rst paper 
we have accepted that describes the design of a 
clinical trial.3
We start from the premise that clinical and 
basic studies require appropriate methods 
and that, hence, development of methods to 
measure simple or complex functions remains one 
of the mainstays of experimental research. Read-
ers of Kidney International have noticed a feature 
called Technical Note, in which we publish, aft er 
appropriate peer review, the development of 
new methods, some of which are applicable to 
patient-oriented research such as measurement 
of the glomerular filtration rate. We will now 
consider similar papers that deal with studies of 
patient-oriented research. Th ey will be subjected 
to the same rigorous review process as the other 
original contributions we receive. Editors will fi rst 
decide whether the study is suffi  ciently original or 
important to warrant review, and if so, the paper 
will be sent out to expert referees in the fi eld who 
will help us in deciding whether to accept them.
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